Setinek U - Search Results

1

Somatic Copy-Number Alterations in Plasma Circulating Tumor DNA from Advanced EGFR-Mutated Lung Adenocarcinoma Patients.

Buder A, Heitzer E, Waldispühl-Geigl J, Weber S, Moser T, Hochmair MJ, Hackner K, Errhalt P, Setinek U, Filipits M. Buder A, et al. Among authors: setinek u. Biomolecules. 2021 Apr 21;11(5):618. doi: 10.3390/biom11050618. Biomolecules. 2021. PMID: 33919291 Free PMC article.

2

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.

Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M. Buder A, et al. Among authors: setinek u. J Thorac Oncol. 2018 Jun;13(6):821-830. doi: 10.1016/j.jtho.2018.02.014. Epub 2018 Mar 2. J Thorac Oncol. 2018. PMID: 29505901 Free article.

3

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.

Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M. Buder A, et al. Among authors: setinek u. Target Oncol. 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x. Target Oncol. 2019. PMID: 30810887 Free PMC article.

4

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib.

Buder A, Hochmair MJ, Setinek U, Pirker R, Filipits M. Buder A, et al. Among authors: setinek u. Transl Lung Cancer Res. 2020 Apr;9(2):239-245. doi: 10.21037/tlcr.2020.03.02. Transl Lung Cancer Res. 2020. PMID: 32420063 Free PMC article.

5

Resistance to EGFR targeting therapies in lung cancer.

Watzka SB, Posch F, Hochmair M, Setinek U, Köstler WJ, Müller MR. Watzka SB, et al. Among authors: setinek u. Minerva Chir. 2011 Oct;66(5):483-94. Minerva Chir. 2011. PMID: 22117213 Review.

6

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis.

Hochmair MJ, Fabikan H, Illini O, Weinlinger C, Setinek U, Krenbek D, Prosch H, Rauter M, Schumacher M, Wöll E, Wass R, Brehm E, Absenger G, Bundalo T, Errhalt P, Urban M, Valipour A. Hochmair MJ, et al. Among authors: setinek u. Pharmaceuticals (Basel). 2020 Nov 7;13(11):371. doi: 10.3390/ph13110371. Pharmaceuticals (Basel). 2020. PMID: 33171712 Free PMC article.

7

Treatment of ALK-rearranged non-small-cell lung cancer with brigatinib as second or later lines: real-world observations from a single institution.

Hochmair M, Weinlinger C, Schwab S, Naber J, Setinek U, Krenbek D, Urban MH, Fabikan H, Watzka S, Koger R, Fazekas A, Bitterlich E, Valipour A, Burghuber OC. Hochmair M, et al. Among authors: setinek u. Anticancer Drugs. 2019 Aug;30(7):e0787. doi: 10.1097/CAD.0000000000000787. Anticancer Drugs. 2019. PMID: 31305295 Clinical Trial.

8

Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study.

Illini O, Fabikan H, Hochmair MJ, Weinlinger C, Krenbek D, Brcic L, Setinek U, Terbuch A, Absenger G, Konjić S, Valipour A. Illini O, et al. Among authors: setinek u. J Clin Med. 2022 Jul 15;11(14):4098. doi: 10.3390/jcm11144098. J Clin Med. 2022. PMID: 35887862 Free PMC article.

9

Rapid Clinical and Radiologic Responses With Larotrectinib Treatment in a Patient With TRK-Fusion-Positive Metastatic Lung Cancer.

Hochmair MJ, Setinek U, Krenbek D, Fazekas A, Illini O, Weinlinger C, Draxler H, Marcher M, Valipour A, Müllauer L, Beer L. Hochmair MJ, et al. Among authors: setinek u. Clin Lung Cancer. 2020 Mar;21(2):e49-e53. doi: 10.1016/j.cllc.2019.11.010. Epub 2019 Nov 20. Clin Lung Cancer. 2020. PMID: 31879191 No abstract available.

10

Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients.

Holzknecht A, Illini O, Hochmair MJ, Krenbek D, Setinek U, Huemer F, Bitterlich E, Kaindl C, Getman V, Akan A, Weber M, Leobacher G, Valipour A, Mueller MR, Watzka SB. Holzknecht A, et al. Among authors: setinek u. Cancers (Basel). 2022 Apr 30;14(9):2245. doi: 10.3390/cancers14092245. Cancers (Basel). 2022. PMID: 35565374 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

42 results

Search Page